Transanal versus laparoscopic total mesorectal excision for mid and low rectal cancer: a meta-analysis of short-term outcomes
- PMID: 31534564
- PMCID: PMC6748052
- DOI: 10.5114/wiitm.2019.82798
Transanal versus laparoscopic total mesorectal excision for mid and low rectal cancer: a meta-analysis of short-term outcomes
Abstract
Introduction: The benefit of transanal total mesorectal excision (TaTME) for mid and low rectal cancer is conflicting.
Aim: To assess and compare the short-term outcomes of TaTME with conventional laparoscopic total mesorectal excision (LaTME) for middle and low rectal cancer.
Material and methods: We searched PubMed, Embase and Cochrane Library databases for studies addressing TaTME versus conventional LaTME for rectal cancer between 2008 and December 2018. Randomized controlled trials (RCTs) and retrospective studies which compared TaTME with LaTME were included.
Results: Twelve retrospective case-control studies were identified, including a total of 899 patients. We did not find significant differences in overall intraoperative complications, blood loss, conversion rate, operative time, overall postoperative complication, anastomotic leakage, ileus, or urinary morbidity. Also no significant differences in oncological outcomes including circumferential resection margin (CRM), positive CRM, distal margin distance (DRM), positive DRM, quality of mesorectum, number of harvested lymph nodes, temporary stoma or local recurrence were found. Although the TaTME group had better postoperative outcomes (readmission, reoperation, length of hospital stay) on average, the difference did not reach statistical significance.
Conclusions: Transanal total mesorectal excision offers a safe and feasible alternative to LaTME although the clinicopathological features were not superior to LaTME in this study. Currently, with the lack of evidence on benefits of TaTME, further evaluation of TaTME requires large randomized control trials to be conducted.
Keywords: laparoscopic total mesorectal excision; meta-analysis; rectal cancer; transanal total mesorectal excision.
Conflict of interest statement
The authors declare no conflict of interest.
Figures








Similar articles
-
[Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer].Zhonghua Wei Chang Wai Ke Za Zhi. 2022 Jun 25;25(6):522-530. doi: 10.3760/cma.j.cn441530-20210811-00321. Zhonghua Wei Chang Wai Ke Za Zhi. 2022. PMID: 35754217 Chinese.
-
Transanal total mesorectal excision (taTME) for rectal cancer: a systematic review and meta-analysis of oncological and perioperative outcomes compared with laparoscopic total mesorectal excision.BMC Cancer. 2016 Jul 4;16:380. doi: 10.1186/s12885-016-2428-5. BMC Cancer. 2016. PMID: 27377924 Free PMC article.
-
Total mesorectal excision for low and middle rectal cancer: laparoscopic versus transanal approach-a meta-analysis.Surg Endosc. 2020 Sep;34(9):3908-3919. doi: 10.1007/s00464-019-07160-8. Epub 2019 Oct 15. Surg Endosc. 2020. PMID: 31617090
-
Meta-analysis of transanal total mesorectal excision versus laparoscopic total mesorectal excision in management of rectal cancer.Int J Colorectal Dis. 2020 Apr;35(4):575-593. doi: 10.1007/s00384-020-03545-7. Epub 2020 Mar 2. Int J Colorectal Dis. 2020. PMID: 32124047
-
Comparison of short-term efficacy of transanal total mesorectal excision and laparoscopic total mesorectal excision in low rectal cancer.Asian J Surg. 2021 Jan;44(1):181-185. doi: 10.1016/j.asjsur.2020.05.007. Epub 2020 May 24. Asian J Surg. 2021. PMID: 32461015
Cited by
-
Natural orifice versus transabdominal specimen extraction in laparoscopic surgery for colorectal cancer: meta-analysis.BJS Open. 2022 May 2;6(3):zrac074. doi: 10.1093/bjsopen/zrac074. BJS Open. 2022. PMID: 35640267 Free PMC article.
-
Transanal total mesorectal excision: 3-year oncological outcomes.Tech Coloproctol. 2021 Feb;25(2):205-213. doi: 10.1007/s10151-020-02362-y. Epub 2020 Oct 28. Tech Coloproctol. 2021. PMID: 33113009
-
Clinical Status and Future Prospects of Transanal Total Mesorectal Excision.Front Oncol. 2022 Jan 3;11:752737. doi: 10.3389/fonc.2021.752737. eCollection 2021. Front Oncol. 2022. PMID: 35047386 Free PMC article. Review.
-
Simple transanal total mesorectal resection versus laparoscopic transabdominal total mesorectal resection for the treatment of low rectal cancer: a single-center retrospective case-control study.Front Surg. 2023 Jul 27;10:1171382. doi: 10.3389/fsurg.2023.1171382. eCollection 2023. Front Surg. 2023. PMID: 37576920 Free PMC article.
-
Comparison of oncological and functional outcomes and quality of life after transanal or laparoscopic total mesorectal excision for rectal cancer: a systematic review and meta-analysis.Tech Coloproctol. 2021 Aug;25(8):901-913. doi: 10.1007/s10151-021-02420-z. Epub 2021 May 17. Tech Coloproctol. 2021. PMID: 34002288
References
-
- Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398–424. - PubMed
-
- Jacobs M, Verdeja JC, Goldstein HS. Minimally invasive colon resection (laparoscopic colectomy) Surg Laparosc Endosc. 1991;1:144–50. - PubMed
-
- Kearney DE, Coffey JC. A Randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015;373:194. - PubMed
-
- Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15:767–74. - PubMed
LinkOut - more resources
Full Text Sources